Compare iShares MSCI Malaysia ETF (EWM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Revvity Inc — how do they compare? iShares MSCI Malaysia ETF trades at $26.66 (market cap $256.41M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 66.2× iShares MSCI Malaysia ETF's market cap, and Revvity Inc pays a 0.18% dividend while iShares MSCI Malaysia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 66 Days and Revvity Inc for 12 Days on average.
| EWM | RVTY | |
|---|---|---|
Market Cap | $256.41M | $16.98B |
Volume | 111,962 | 1,456,900 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $157.36 |
52-Week Low | $25.33 | $82.26 |
Typical Hold Time | 66 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM stock trades at $26.66 with minimal daily movement (+0.19%). Technical indicators show conflicting signals with moving averages suggesting bearish pressure while oscillators indicate potential oversold conditions. The stock faces immediate resistance at $27 and support at $26. Recent news highlights regional environmental challenges affecting operations.
The stock presents a cautious outlook with mixed technical signals and limited fundamental data available. Near-term direction will depend on earnings results and management guidance. Key risks include operational disruptions from regional environmental issues and broader market volatility affecting small-cap stocks.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
